Last $0.0050 USD
Change Today 0.00 / 0.00%
Volume 0.0
NEUKF On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

neurokine pharmaceuticals (NEUKF) Snapshot

Open
$0.0050
Previous Close
$0.0050
Day High
$0.0050
Day Low
$0.0050
52 Week High
03/28/14 - $0.04
52 Week Low
12/5/14 - $0.0012
Market Cap
578.8K
Average Volume 10 Days
3.0K
EPS TTM
$-0.0010
Shares Outstanding
115.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROKINE PHARMACEUTICALS (NEUKF)

Related News

No related news articles were found.

neurokine pharmaceuticals (NEUKF) Related Businessweek News

No Related Businessweek News Found

neurokine pharmaceuticals (NEUKF) Details

Neurokine Pharmaceuticals Inc., a development stage company, engages in the development and commercialization of therapeutic pharmaceutical products. The company focuses on biologics comprising vaccines, blood, and blood components; allergenics; somatic cells relating to the wall of the body cavity; gene therapy; tissues; and recombinant therapeutics that cause cell death in tumors. Its products under the developmental stage include NK-001 for the potential treatment of neurocognitive impairment in post-coronary artery bypass graft surgery patients; and NK-002 for the potential treatment of Alzheimer’s disease. The company was formerly known as Xerxes Health Corp. and changed its name to Neurokine Pharmaceuticals Inc. in June 2007. Neurokine Pharmaceuticals Inc. was founded in 2002 and is based in Vancouver, Canada.

neurokine pharmaceuticals (NEUKF) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

neurokine pharmaceuticals (NEUKF) Key Developments

Neurokine Pharmaceuticals Inc. Approves Adoption of New Articles and Cancellation of Current Articles

On September 26, 2014, Neurokine Pharmaceuticals Inc. held a special meeting of stockholders to approve the removal of company's Pre-Existing Company Provisions, the cancellation of current Articles and the adoption of new articles and to approve a reverse stock split on the basis of up to 1:100.

Neurokine Pharmaceuticals Inc., Special/Extraordinary Shareholders Meeting, Sep 26, 2014

Neurokine Pharmaceuticals Inc., Special/Extraordinary Shareholders Meeting, Sep 26, 2014., at 10:00 Pacific Standard Time. Location: 400 - 570 Granville Street. Agenda: To consider and approve a special resolution removing the application of the Pre-Existing Company Provisions of the company, and altering the notice of Articles of the company; to consider and approve a special resolution deleting company’s current Articles and creating and adopting the Articles set out in Schedule ‘A’ to the accompanying Proxy Statement as the Articles of the company, subject to the PCP Removal Proposal; to approve a reverse stock split (consolidation) of the company's issued and outstanding common shares on basis of up to 100:1; and to transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

Neurokine Pharmaceuticals Inc. Announces Management Changes

On July 24, 2014, Maziar Badii and Richard Azani resigned as directors of Neurokine Pharmaceuticals Inc. The resignations of Maziar Badii and Richard Aazani were not the result of any disagreements with company regarding operations, policies, practices or otherwise. In addition, Hamid Doroudian resigned as president, chief executive officer and secretary. On July 24, 2014, the company appointed Patrick C. Frankham and Hamid Doroudian as directors of company and appointed Ahmad Doroudian, a current director, as president, chief executive officer and secretary. Dr. Frankham has over 18 years of experience in the biopharmaceutical and services industries. Prior to joining Boehringer Ingelheim, he founded several multinational healthcare startup enterprises including healthcare information technology, services and pharmaceuticals companies. Dr. Doroudian was appointed as president, chief executive officer and secretary on August 30, 2011. Dr. Doroudian has over 20 years experience in managing and overseeing clinical research and development of pharmaceutical products. Dr. Doroudian is a founder and owner of Pharmex Rom Industry Ltd. Dr. Doroudian has served as general manager of Pharmex Rom Industry Ltd. since 1992 where his duties have included overseeing all aspects of Pharmex’s business, including clinical research and product development, regulatory affairs, licensing, distribution, and general operations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEUKF:US $0.01 USD 0.00

NEUKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEUKF.
View Industry Companies
 

Industry Analysis

NEUKF

Industry Average

Valuation NEUKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROKINE PHARMACEUTICALS, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.